Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Arhaus, Inc. (ARHS)
NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-11-04
$12.94-1.60%
Close 2026-11-05 · 1-day change
NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.57 → 0.58 EPS · FY ending Dec 31, 2027 · 12 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 11 to 12; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ARHS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve adjusted EBITDA through cost control | A supporting condition in Arhaus, Inc.'s published investment case. The stated target is Maintain or improve adjusted EBITDA margin. | Improving | Adjusted EBITDA margin declines meaningfully next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ARHS is a growth-oriented consumer discretionary business with recent financial performance in the stronger half of its industry. Its long-term thesis is intact, but this is not a low-risk setup: management and earnings quality are rated neutral, while overall risk is elevated.
The valuation is expensive versus peers, with a 1.76 premium, though confidence in that estimate is low. The expectations gap is moderate, and the evidence points to valuation as the main source of fragility rather than a combination of weak results and turbulence.
Near term, recent results show improving revenue growth, from 0.9% year-over-year in the first quarter to 7.4% in the second quarter. Adjusted EBITDA rose 16.8% in the second quarter after falling 3.1% in the first, so improvement is real but uneven; capital spending remains within management’s stated annual range. The next guidance update is a key risk, with smaller company size and a downward trend in earnings surprises adding caution despite a low estimated miss probability.
Over the next few quarters, the thesis depends on maintaining revenue growth, improving adjusted EBITDA with less variation, and keeping capital spending within plan. A guidance cut would weaken the near-term case. Results and guidance from consumer discretionary leaders such as AMZN, BABA, and PDD could also strengthen or reduce the sector tailwind.
For the 1-to-3-year view, ARHS has improving recent fundamentals and an intact thesis, but its expensive peer valuation makes continued execution important. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Arhaus, Inc.'s published investment case. The stated target is $70M to $90M. |
| Intact |
| Capital spending exceeds $90M or falls below $70M in FY26 |
Capital expenditures: $21.213M FY2026-Q2; GAAP. Published target: $70M to $90M. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202621,213,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Company-funded capital expenditures (5) were $29 million and landlord contributions were $8 million.” “Company-funded capital expenditures (5) were $13 million and landlord contributions were $3 million.” Delivery assessment Nov 4, 2026 |
Sustain revenue growth to about $1.45B in FY26 | A primary condition in Arhaus, Inc.'s published investment case. The stated target is ~$1.45B. | Under Pressure | Revenue falls below $1.43B in FY26 | Revenue: $384.897M FY2026-Q2; GAAP. Published target: ~$1.45B. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026384,897,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Business Highlights Second quarter net revenue was $385 million, an increase of 7.4% year-over-year and above the high end of the Company’s guidance range.” “For 2026, the Company continues to expect to complete approximately 10 to 14 Total Showroom Projects (3) , consisting of 4 to 6 new openings and 6 to 8 relocations, renovations, or expansions, representing Net Unit Growth (4) of mid-single-digits for the year.” Revenue was $384.897 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.55 → $0.58 · observed estimates
$1.54B → $1.56B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.55 | $1,537,864,500 | 14 / 13 |
| 2026-07-25 | $0.55 | $1,538,356,810 | 14 / 13 |
| 2026-07-26 | $0.55 | $1,538,356,810 | 14 / 13 |
| 2026-07-27 | $0.55 | $1,538,364,500 | 14 / 13 |
| 2026-07-28 | $0.55 | $1,538,364,500 | 14 / 13 |
| 2026-07-29 | $0.55 | $1,538,364,500 | 14 / 13 |
| 2026-07-30 | $0.55 | $1,538,364,500 | 14 / 13 |
| 2026-07-31 | $0.55 | $1,538,364,500 | 14 / 13 |
| 2026-08-01 | $0.55 | $1,538,364,500 | 14 / 13 |
| 2026-08-02 | $0.55 | $1,538,364,500 | 14 / 13 |
| 2026-08-03 | $0.55 | $1,538,364,500 | 14 / 13 |
| 2026-08-04 | $0.55 | $1,538,364,500 | 14 / 13 |
| 2026-08-05 | $0.55 | $1,538,607,820 | 14 / 13 |
| 2026-08-06 | $0.55 | $1,538,607,820 | 14 / 13 |
| 2026-08-07 | $0.55 | $1,538,598,861 | 11 / 10 |
| 2026-08-08 | $0.57 | $1,547,192,040 | 12 / 13 |
| 2026-08-09 | $0.57 | $1,547,192,040 | 12 / 13 |
| 2026-08-10 | $0.57 | $1,547,192,040 | 12 / 13 |
| 2026-08-11 | $0.57 | $1,552,768,960 | 14 / 13 |
| 2026-08-12 | $0.57 | $1,552,768,960 | 14 / 13 |
| 2026-08-13 | $0.57 | $1,552,768,960 | 14 / 13 |
| 2026-08-14 | $0.55 | $1,538,598,861 | 11 / 10 |
| 2026-08-15 | $0.55 | $1,538,598,861 | 11 / 10 |
| 2026-08-16 | $0.55 | $1,538,598,861 | 11 / 10 |
| 2026-08-17 | $0.55 | $1,538,598,861 | 11 / 10 |
| 2026-08-18 | $0.55 | $1,538,598,861 | 11 / 10 |
| 2026-08-19 | $0.55 | $1,538,598,861 | 11 / 10 |
| 2026-08-20 | $0.56 | $1,551,003,184 | 11 / 10 |
| 2026-08-21 | $0.56 | $1,551,003,184 | 11 / 10 |
| 2026-08-22 | $0.56 | $1,551,003,184 | 11 / 10 |
| 2026-08-23 | $0.56 | $1,551,003,184 | 11 / 10 |
| 2026-08-24 | $0.56 | $1,551,003,184 | 11 / 10 |
| 2026-08-25 | $0.56 | $1,551,003,184 | 11 / 11 |
| 2026-08-26 | $0.56 | $1,551,667,242 | 11 / 11 |
| 2026-08-27 | $0.56 | $1,551,667,242 | 11 / 11 |
| 2026-08-28 | $0.56 | $1,551,667,242 | 11 / 11 |
| 2026-08-29 | $0.56 | $1,551,667,242 | 11 / 11 |
| 2026-08-30 | $0.56 | $1,551,667,242 | 11 / 11 |
| 2026-08-31 | $0.56 | $1,551,667,242 | 11 / 11 |
| 2026-09-01 | $0.56 | $1,551,667,242 | 11 / 11 |
| 2026-09-02 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-03 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-04 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-05 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-06 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-07 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-08 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-09 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-10 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-11 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-12 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-13 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-14 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-15 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-16 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-17 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-18 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-19 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-20 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-21 | $0.57 | $1,551,667,242 | 11 / 11 |
| 2026-09-22 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-09-23 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-09-24 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-09-25 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-09-26 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-09-27 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-09-28 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-09-29 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-09-30 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-10-01 | $0.57 | $1,552,624,385 | 11 / 11 |
| 2026-10-02 | $0.57 | $1,552,623,830 | 11 / 11 |
| 2026-10-03 | $0.57 | $1,552,623,830 | 11 / 11 |
| 2026-10-04 | $0.57 | $1,552,623,830 | 11 / 11 |
| 2026-10-05 | $0.57 | $1,552,623,830 | 11 / 11 |
| 2026-10-06 | $0.57 | $1,552,623,830 | 11 / 11 |
| 2026-10-07 | $0.57 | $1,553,788,671 | 11 / 11 |
| 2026-10-08 | $0.57 | $1,553,788,671 | 12 / 11 |
| 2026-10-09 | $0.57 | $1,553,788,671 | 12 / 11 |
| 2026-10-10 | $0.57 | $1,553,788,671 | 12 / 11 |
| 2026-10-11 | $0.57 | $1,553,788,671 | 12 / 11 |
| 2026-10-12 | $0.57 | $1,553,788,671 | 12 / 11 |
| 2026-10-13 | $0.57 | $1,553,788,671 | 12 / 11 |
| 2026-10-14 | $0.57 | $1,553,787,784 | 12 / 11 |
| 2026-10-15 | $0.57 | $1,553,787,784 | 12 / 11 |
| 2026-10-16 | $0.57 | $1,553,787,784 | 12 / 11 |
| 2026-10-17 | $0.57 | $1,553,787,784 | 12 / 11 |
| 2026-10-18 | $0.57 | $1,554,859,213 | 12 / 11 |
| 2026-10-19 | $0.57 | $1,554,859,213 | 12 / 11 |
| 2026-10-20 | $0.57 | $1,554,859,213 | 12 / 11 |
| 2026-10-21 | $0.58 | $1,557,307,312 | 12 / 11 |
| 2026-10-22 | $0.58 | $1,557,307,312 | 12 / 11 |
| 2026-10-23 | $0.58 | $1,557,307,312 | 12 / 11 |
| 2026-10-24 | $0.58 | $1,557,307,312 | 12 / 11 |
| 2026-10-25 | $0.58 | $1,557,307,312 | 12 / 11 |
| 2026-10-26 | $0.58 | $1,557,307,312 | 12 / 11 |
| 2026-10-27 | $0.58 | $1,557,307,312 | 12 / 11 |
| 2026-10-28 | $0.58 | $1,557,307,312 | 12 / 11 |
| 2026-10-29 | $0.58 | $1,557,307,312 | 12 / 11 |
| 2026-10-30 | $0.58 | $1,559,315,663 | 12 / 11 |
| 2026-10-31 | $0.58 | $1,559,315,342 | 12 / 11 |
| 2026-11-01 | $0.58 | $1,559,315,342 | 12 / 11 |
| 2026-11-02 | $0.58 | $1,559,315,342 | 12 / 11 |
| 2026-11-03 | $0.58 | $1,559,315,342 | 12 / 11 |
| 2026-11-04 | $0.58 | $1,559,315,342 | 12 / 11 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 7 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.